Overview L19IL2/L19TNF in Skin Cancer Patients Status: Not yet recruiting Trial end date: 2024-12-01 Target enrollment: Participant gender: Summary Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention. Phase: Phase 2 Details Lead Sponsor: Philogen S.p.A.